scholarly journals Heparin in the Prevention of Deep Vein Thrombosis after Myocardial Infarction

BMJ ◽  
1972 ◽  
Vol 2 (5811) ◽  
pp. 436-438 ◽  
Author(s):  
A. J. Handley ◽  
P. A. Emerson ◽  
P. R. Fleming
Author(s):  
Imi Faghmous ◽  
Francis Nissen ◽  
Peter Kuebler ◽  
Carlos Flores ◽  
Anisha M Patel ◽  
...  

Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.


2021 ◽  
pp. 14-16
Author(s):  
J Mariano Anto Brunomascarenhas

BACKGROUND: As we are in the middle of the second year of the COVID19 Pandemic,we are observing an increased incidence of conditions like Cerebrovascular Accidents, Ischemic Heart Disease, Myocardial Infarction, Deep Vein Thrombosis,Pulmonary Embolism,and Thrombosis of Other Vessels. MATERIALS AND METHODS: Literature Review and Analysis of Coagulation Profiles of Patients in the past 1 year treated by the author was done. RESULTS AND CONCLUSIONS: 1. COVID19 is not just an infectious disease, but also an Immune Disease. The Immune Part can also happen in Asymptomatic Patients and those who got the vaccine. 2. Most of the disease processes in the body start after the virus has been cleared from the throat. The vigil against complications must not stop when the Throat Swab becomes negative or even when the patient is discharged but must continue for months till all the disease processes stop. 3.It is recommended that: a.Initial Evaluation with PT, aPTT, INR is done for: I.Those suffering from COVID 19 who have not undergone D Dimer evaluation ii.Those recovering from COVID 19. iii.Those likely to have had COVID 19 (based on the symptoms),but the infection was not documented. iv.Those likely to have had asymptomatic COVID 19 (contacts of COVID19 infected patients) v.Those planning to take Vaccines for COVID19. b.An Abnormal Value in PT,aPTT,INR may be managed with appropriate Drugs like Aspirin,Clopidogrel,Dipyridamole, Ticlopidine, Rivaroxaban, Dabigatran, Apixaban, Edoxaban, Heparin, Low Molecular Weight Heparin, Warfarin, and other drugs. c. Serial Evaluation of PT, aPTT, INR be done after 1 month, 3 months, 6 months (and even at more frequent intervals if indicated) and the drugs are added or removed,the dosage of the drugs is increased or reduced based on the results. d.Standard Indication of IVC Filter may be followed. 4.It is the knowledge of the pathogenesis of Thrombosis that is crucial in the prevention and management of Stroke, Heart Attack, Deep Vein Thrombosis, and Pulmonary Embolism rather than fancy gadgets, expensive tests, and exotic drugs.


1985 ◽  
Vol 54 (02) ◽  
pp. 503-505 ◽  
Author(s):  
Jørgen Gram ◽  
Jørgen Jespersen

SummaryIn a longitudinal study the plasma levels of antithrombin-III, α2-macroglobulin, α2-antiplasmin, histidine-rich glycoprotein, and protein C were followed in two groups of patients with acute myocardial infarction (AMI), one with and one without deep vein thrombosis (DVT). None of the sequentially studied periods revealed significant differences between the two groups of patients. However, small but consistently higher levels of histidine-rich glycoprotein in patients with DVT suggested the existence among patients submitted for myocardial infarction of a subgroup with increased thrombophilic potential. It was concluded that the inhibitors studied are of little value as possible indicators of the presence of DVT at early stages of the disease when clinical signs are absent and when antithrombotic prophylaxis should preferably be initiated.


Spine ◽  
2018 ◽  
Vol 43 (13) ◽  
pp. E766-E772 ◽  
Author(s):  
Brian Shiu ◽  
Elizabeth Le ◽  
Ehsan Jazini ◽  
Tristan B. Weir ◽  
Timothy Costales ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document